Jerome Boursier

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5880486/publications.pdf

Version: 2024-02-01

139	10,811	47006	32842
papers	citations	47	100
		h-index	g-index

142	142	142	10343
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology, 2016, 63, 764-775.	7.3	1,029
2	Elafibranor, an Agonist of the Peroxisome Proliferatorâ^'Activated Receptorâ^'Î± andÂâ^'Î´, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology, 2016, 150, 1147-1159.e5.	1.3	847
3	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.	13.7	818
4	EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis â€“ 2021 update. Journal of Hepatology, 2021, 75, 659-689.	3.7	676
5	Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology, 2013, 57, 1182-1191.	7.3	466
6	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. The Lancet Gastroenterology and Hepatology, 2020, 5, 362-373.	8.1	411
7	Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology, 2016, 63, 1817-1827.	7.3	388
8	A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. New England Journal of Medicine, 2018, 378, 2171-2181.	27.0	383
9	Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. Journal of Hepatology, 2016, 65, 570-578.	3.7	300
10	Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the Heterogeneity of the Human Disease. PLoS ONE, 2015, 10, e0127991.	2.5	261
11	Comparison of blood tests for liver fibrosis specific or not to NAFLD. Journal of Hepatology, 2009, 50, 165-173.	3.7	230
12	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut, 2022, 71, 1006-1019.	12.1	195
13	Prednisolone With vs Without Pentoxifylline and Survival of Patients With Severe Alcoholic Hepatitis. JAMA - Journal of the American Medical Association, 2013, 310, 1033.	7.4	181
14	Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology, 2020, 73, 252-262.	3.7	170
15	Prognostic accuracy of FIBâ€4, NAFLD fibrosis score and APRI for NAFLDâ€related events: A systematic review. Liver International, 2021, 41, 261-270.	3.9	155
16	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology, 2021, 75, 770-785.	3.7	149
17	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. The Lancet Gastroenterology and Hepatology, 2020, 5, 970-985.	8.1	142
18	Acoustic radiation force impulse: a new ultrasonographic technology for the widespread noninvasive diagnosis of liver fibrosis. European Journal of Gastroenterology and Hepatology, 2010, 22, 1074-1084.	1.6	126

#	Article	IF	Citations
19	Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC. Journal of Hepatology, 2017, 66, 67-74.	3.7	123
20	Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. Hepatology, 2014, 60, 65-76.	7.3	118
21	Reproducibility of Liver Stiffness Measurement by Ultrasonographic Elastometry. Clinical Gastroenterology and Hepatology, 2008, 6, 1263-1269.	4.4	113
22	Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology, 2012, 55, 58-67.	7.3	112
23	Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. Journal of Hepatology, 2021, 74, 1109-1116.	3.7	112
24	Implication of Gut Microbiota in Nonalcoholic Fatty Liver Disease. PLoS Pathogens, 2015, 11, e1004559.	4.7	111
25	ILâ€34 and macrophage colonyâ€stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells. Hepatology, 2014, 60, 1879-1890.	7.3	107
26	New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD. Journal of Hepatology, 2019, 71, 389-396.	3.7	107
27	The combination of a blood test and Fibroscan improves the nonâ€invasive diagnosis of liver fibrosis. Liver International, 2009, 29, 1507-1515.	3.9	105
28	Learning curve and interobserver reproducibility evaluation of liver stiffness measurement by transient elastography. European Journal of Gastroenterology and Hepatology, 2008, 20, 693-701.	1.6	95
29	Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver International, 2008, 28, 1352-1362.	3.9	94
30	Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. The Lancet Gastroenterology and Hepatology, 2018, 3, 614-625.	8.1	91
31	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 806-815.e5.	4.4	90
32	A New Combination of Blood Test and Fibroscan for Accurate Non-Invasive Diagnosis of Liver Fibrosis Stages in Chronic Hepatitis C. American Journal of Gastroenterology, 2011, 106, 1255-1263.	0.4	87
33	Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis. Gut, 2015, 64, 1148-1157.	12.1	84
34	Disease burden and economic impact of diagnosed nonâ€alcoholic steatohepatitis in five European countries in 2018: A costâ€ofâ€illness analysis. Liver International, 2021, 41, 1227-1242.	3.9	76
35	Nonalcoholic Fatty Liver Disease and the Gut Microbiome. Clinics in Liver Disease, 2016, 20, 263-275.	2.1	73
36	A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. Journal of Hepatology, 2017, 66, 1158-1165.	3.7	71

#	Article	IF	Citations
37	Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: A meta-analysis with individual data. Clinical Biochemistry, 2008, 41, 1368-1376.	1.9	69
38	Long-term follow-up after endoscopic resection for superficial esophageal squamous cell carcinoma: a multicenter Western study. Endoscopy, 2019, 51, 298-306.	1.8	67
39	Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. Journal of Hepatology, 2022, 76, 1013-1020.	3.7	66
40	Comparison and Improvement of MELD and Child-Pugh Score Accuracies for the Prediction of 6-month Mortality in Cirrhotic Patients. Journal of Clinical Gastroenterology, 2009, 43, 580-585.	2.2	59
41	Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. European Journal of Gastroenterology and Hepatology, 2009, 21, 28-38.	1.6	58
42	Radiologic versus Endoscopic Placement of Percutaneous Gastrostomy in Amyotrophic Lateral Sclerosis: Multivariate Analysis of Tolerance, Efficacy, and Survival. Journal of Vascular and Interventional Radiology, 2010, 21, 527-533.	0.5	56
43	Screening for therapeutic trials and treatment indication in clinical practice: <scp>MACK</scp>â€3, a new blood test for the diagnosis of fibrotic <scp>NASH</scp>. Alimentary Pharmacology and Therapeutics, 2018, 47, 1387-1396.	3.7	55
44	An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: The Liver-FibroSTARD standards. Journal of Hepatology, 2015, 62, 807-815.	3.7	54
45	Precise evaluation of liver histology by computerized morphometry shows that steatosis influences liver stiffness measured by transient elastography in chronic hepatitis C. Journal of Gastroenterology, 2014, 49, 527-537.	5.1	53
46	Incidental focal solid liver lesions: diagnostic performance of contrast-enhanced ultrasound and MR imaging. European Radiology, 2010, 20, 1715-1725.	4.5	52
47	Portosystemic collateral vessels in liver cirrhosis: a three-dimensional MDCT pictorial review. Abdominal Radiology, 2012, 37, 746-766.	2.1	52
48	Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. European Radiology, 2011, 21, 1719-1726.	4.5	49
49	IL-26 is overexpressed in chronically HCV-infected patients and enhances TRAIL-mediated cytotoxicity and interferon production by human NK cells. Gut, 2015, 64, 1466-1475.	12.1	49
50	FibroMeters: a family of blood tests for liver fibrosis. Gastroenterologie Clinique Et Biologique, 2008, 32, 40-51.	0.9	47
51	Optimization and robustness of blood tests for liver fibrosis and cirrhosis. Clinical Biochemistry, 2010, 43, 1315-1322.	1.9	42
52	Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease. Liver International, 2010, 30, 1346-1354.	3.9	41
53	Phenotyping of circulating extracellular vesicles (EVs) in obesity identifies large EVs as functional conveyors of Macrophage Migration Inhibitory Factor. Molecular Metabolism, 2018, 18, 134-142.	6.5	40
54	Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0238717.	2.5	40

#	Article	IF	Citations
55	Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. Gut, 2022, 71, 402-414.	12.1	39
56	Direct comparison of the specialised blood fibrosis tests FibroMeter^{V2G} and Enhanced Liver Fibrosis score in patients with nonâ€alcoholic fatty liver disease from tertiary care centres. Alimentary Pharmacology and Therapeutics, 2019, 50, 1214-1222.	3.7	38
57	Association Between Severity of Obstructive Sleep Apnea and Blood Markers of Liver Injury. Clinical Gastroenterology and Hepatology, 2016, 14, 1657-1661.	4.4	37
58	Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liverâ€prognosis in chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2014, 40, 178-188.	3.7	36
59	Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in General Population: the French Nationwide NASH-CO Study. Gastroenterology, 2020, 159, 791-793.e2.	1.3	36
60	Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications. Clinical Gastroenterology and Hepatology, 2023, 21, 1243-1251.e12.	4.4	32
61	Improved fibrosis staging by elastometry and blood test in chronic hepatitis C. Liver International, 2014, 34, 907-917.	3.9	28
62	Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions!. Clinical and Translational Gastroenterology, 2019, 10, e00023.	2.5	28
63	Large oesophageal varice screening by a sequential algorithm using a cirrhosis blood test and optionally capsule endoscopy. Liver International, 2018, 38, 84-93.	3.9	27
64	Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. Atherosclerosis, 2018, 278, 82-90.	0.8	27
65	Liver fibrosis, cirrhosis, and cirrhosis-related nodules: Imaging diagnosis and surveillance. Diagnostic and Interventional Imaging, 2017, 98, 455-468.	3.2	26
66	Fatty liver index is a strong predictor of changes in glycemic status in people with prediabetes: The IT-DIAB study. PLoS ONE, 2019, 14, e0221524.	2.5	26
67	Transient Versus Twoâ€Dimensional Shearâ€Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD. Hepatology, 2021, 73, 2196-2205.	7.3	25
68	Noninvasive liver steatosis quantification using MRI techniques combined with blood markers. European Journal of Gastroenterology and Hepatology, 2010, 22, 973-982.	1.6	24
69	Controlled attenuation parameter (<scp>CAP</scp>): a new device for fast evaluation of liver fat?. Liver International, 2012, 32, 875-877.	3.9	24
70	Radiofrequency ablation of hepatocellular carcinoma: Mono or multipolar?. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 654-660.	2.8	24
71	FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 2415.	2.4	24
72	Increased liver stiffness in patients with severe sleep apnoea and metabolic comorbidities. European Respiratory Journal, 2018, 51, 1800601.	6.7	23

#	Article	IF	Citations
73	Obstructive sleep apnea, chronic obstructive pulmonary disease and NAFLD: an individual participant data meta-analysis. Sleep Medicine, 2021, 77, 357-364.	1.6	23
74	Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C. BMC Gastroenterology, 2011, 11, 132.	2.0	22
75	Osteoprotegerin levels are associated with liver fat and liver markers in dysmetabolic adults. Diabetes and Metabolism, 2016, 42, 364-367.	2.9	22
76	Spirulina Liquid Extract Protects against Fibrosis Related to Non-Alcoholic Steatohepatitis and Increases Ursodeoxycholic Acid. Nutrients, 2019, 11, 194.	4.1	20
77	Quantification of portalâ€“bridging fibrosis area more accurately reflects fibrosis stage and liver stiffness than whole fibrosis or perisinusoidal fibrosis areas in chronic hepatitis C. Modern Pathology, 2014, 27, 1035-1045.	5.5	19
78	Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. Clinical Gastroenterology and Hepatology, 2021, 19, 777-787.e17.	4.4	19
79	Case-finding strategies in non-alcoholic fatty liver disease. JHEP Reports, 2021, 3, 100219.	4.9	19
80	A not so solitary fibrous tumor of the liver. Gastroenterologie Clinique Et Biologique, 2010, 34, 716-720.	0.9	18
81	MRI measurement of liver fat content predicts the metabolic syndrome. Diabetes and Metabolism, 2013, 39, 314-321.	2.9	18
82	Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. Diabetes and Metabolism, 2021, 47, 101272.	2.9	18
83	Liverâ€related and extrahepatic events in patients with nonâ€alcoholic fatty liver disease: a retrospective competing risks analysis. Alimentary Pharmacology and Therapeutics, 2022, 55, 604-615.	3.7	18
84	Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis?. American Journal of Physiology - Renal Physiology, 2021, 320, G485-G495.	3.4	17
85	Steatosis degree, measured by morphometry, is linked to other liver lesions and metabolic syndrome components in patients with NAFLD. European Journal of Gastroenterology and Hepatology, 2011, 23, 974-981.	1.6	16
86	Liver fibrosis diagnosis by blood test and elastography in chronic hepatitis C: agreement or combination?. Alimentary Pharmacology and Therapeutics, 2017, 45, 991-1003.	3.7	16
87	Large Extracellular Vesicle-Associated Rap1 Accumulates in Atherosclerotic Plaques, Correlates With Vascular Risks and Is Involved in Atherosclerosis. Circulation Research, 2020, 127, 747-760.	4.5	16
88	Microbiotaâ€derived extracellular vesicles and metabolic syndrome. Acta Physiologica, 2021, 231, e13600.	3.8	16
89	Anti-diabetic drugs and NASH: from current options to promising perspectives. Expert Opinion on Investigational Drugs, 2021, 30, 813-825.	4.1	16
90	Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1750-1756.	2.8	15

#	Article	IF	Citations
91	Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database. EClinicalMedicine, 2020, 25, 100445.	7.1	15
92	Endoscopic treatment of painful chronic pancreatitis: Evaluation of a new flexible multiperforated plastic stent. Gastroenterologie Clinique Et Biologique, 2008, 32, 801-805.	0.9	14
93	Clinical interpretation of FibroscanÂ® results: a real challenge. Liver International, 2010, 30, 1400-1402.	3.9	14
94	Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests. Gastroenterologie Clinique Et Biologique, 2008, 32, 1050-1060.	0.9	12
95	Reliability Criteria of Two-Dimensional Shear Wave Elastography: Analysis of 4277 Measurements in 788 Patients. Clinical Gastroenterology and Hepatology, 2022, 20, 400-408.e10.	4.4	12
96	LPS-enriched small extracellular vesicles from metabolic syndrome patients trigger endothelial dysfunction by activation of TLR4. Metabolism: Clinical and Experimental, 2021, 118, 154727.	3.4	12
97	Assessment of new hyaluronic acid assays and their impact on FibroMeter scores. Clinica Chimica Acta, 2011, 412, 347-352.	1.1	11
98	Prognostic durability of liver fibrosis tests and improvement in predictive performance for mortality by combining tests. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1240-1249.	2.8	11
99	Criteria to Determine Reliability of Noninvasive Assessment of Liver Fibrosis With Virtual Touch Quantification. Clinical Gastroenterology and Hepatology, 2019, 17, 164-171.e5.	4.4	11
100	Quality criteria for the measurement of liver stiffness. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101761.	1.5	10
101	Management of alcoholâ€related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines. Liver International, 2022, 42, 1330-1343.	3.9	10
102	Combination of fibrosis tests: Sequential or synchronous?. Hepatology, 2009, 50, 656-657.	7.3	9
103	Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice. Expert Opinion on Medical Diagnostics, 2012, 6, 381-394.	1.6	8
104	MRI versus histological methods for time course monitoring of steatosis amount in a murine model of NAFLD. Diagnostic and Interventional Imaging, 2015, 96, 915-922.	3.2	8
105	Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?. Journal of Hepatology, 2017, 66, 304-312.	3.7	8
106	Non-invasive diagnosis and follow-up of non-alcoholic fatty liver disease. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101769.	1.5	8
107	Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101848.	1.5	8
108	Treatment of liver fibrosis: Clinical aspects. Gastroenterologie Clinique Et Biologique, 2009, 33, 958-966.	0.9	7

#	Article	IF	Citations
109	Liver fibrogenesis and genetic factors. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, S3-S9.	1.5	7
110	Cirrhosis Diagnosis and Liver Fibrosis Staging. Journal of Clinical Gastroenterology, 2015, 49, 512-519.	2.2	7
111	Noninvasive Tests of Liver Fibrosis and Their Combination in Nonalcoholic Fatty Liver Disease: From Selected Patients to Realâ€Life Populations. Hepatology, 2019, 70, 1500-1502.	7.3	7
112	Non-invasive diagnosis of patients with â€˜at-riskâ€™ NAFLD : only fibrosis counts?. Gut, 2020, 69, 1164-1165.	12.1	7
113	Crossâ€linkage between bacterial taxonomy and gene functions: a study of metagenomeâ€assembled genomes of gut microbiota in adult nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2021, 53, 722-732.	3.7	7
114	Noninvasive Algorithms for the Case Finding of â€œAt-Riskâ€•Patients with NAFLD. Seminars in Liver Disease, 2022, 42, 313-326.	3.6	7
115	Screening for significant chronic liver disease by using three simple ultrasound parameters. European Journal of Radiology, 2015, 84, 1466-1472.	2.6	6
116	Fibrosis assessment using FibroMeter combined to first generation tests in hepatitis C. World Journal of Hepatology, 2017, 9, 310.	2.0	6
117	Doppler ultrasonography devices, including elastography, allow for accurate diagnosis of severe liver fibrosis. European Journal of Radiology, 2018, 108, 133-139.	2.6	5
118	A single blood test adjusted for different liver fibrosis targets improves fibrosis staging and especially cirrhosis diagnosis. Hepatology Communications, 2018, 2, 455-466.	4.3	4
119	Nonâ€selective betaâ€blockers increase overall and liver mortality in alcoholic cirrhosis with MELDÂâ‰¥Â12 over 5 years of followâ€up. Liver International, 2021, 41, 168-179.	3.9	4
120	Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study. PLoS ONE, 2022, 17, e0266965.	2.5	4
121	Metastatic hepatocellular carcinoma: When surgery and successive palliative treatments lead to remission. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, e19-e22.	1.5	3
122	Simple blood fibrosis tests reduce unnecessary referrals for specialized evaluations of liver fibrosis in NAFLD and ALD patients. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 349-355.	1.5	3
123	Ultrasonographic elastometry vs. blood tests for the diagnosis of cirrhosis: A Pyrrhic victory?. Journal of Hepatology, 2009, 51, 228-229.	3.7	2
124	The combination of Fibroscan with blood markers in the fibrometerVCTE significantly reduces the use of liver biopsy for the assessment of advanced fibrosis in non-alcoholic fatty liver disease. Journal of Hepatology, 2017, 66, S161-S162.	3.7	2
125	Noninvasive diagnosis of liver fibrosis in NAFLD: Tips tricks. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 658-662.	1.5	2
126	Apple Supplementation Improves Hemodynamic Parameter and Attenuates Atherosclerosis in High-Fat Diet-Fed Apolipoprotein E-Knockout Mice. Biomedicines, 2020, 8, 495.	3.2	2

#	Article	IF	Citations
127	Obstructive sleep apnoea and non-alcoholic fatty liver disease: Which patients should be referred to hepatologists?. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, e90-e92.	1.5	1
128	Quality Criteria for Liver Stiffness Measurement by Transient Elastography. , 2020, , 479-494.		1
129	Reply to: Correspondence on â€œEASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis â€“ 2021 updateâ€• Journal of Hepatology, 2022, 76, 251-252.	3.7	1
130	Determinants of the severity of fatty liver diseases: Need all the pieces to solve the puzzle. Hepatology, 2022, 75, 782-784.	7.3	1
131	Which would you prefer for a liver fibrosis test: A limited fixed menu or a gourmet buffet?. Gastroenterologie Clinique Et Biologique, 2009, 33, 388-389.	0.9	0
132	Response to Munteanu et al.. American Journal of Gastroenterology, 2011, 106, 1853-1854.	0.4	0
133	The <scp>CUPIC</scp> algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients. Journal of Viral Hepatitis, 2015, 22, 1002-1010.	2.0	0
134	Reply. Hepatology, 2016, 64, 994-995.	7.3	0
135	Editorial: combining elastography with blood test for fibrosis assessment in chronic hepatitis C â€“ authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 1276-1277.	3.7	0
136	Reply to: â€œPitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FM VCTE algorithmâ€•and to â€œApplication of the new eLIFT test for the non-invasive diagnosis of advanced liver fibrosis in people with type 2 diabetesâ€• Journal of Hepatology, 2018, 68, 605-606.	3.7	0
137	Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease and Liver Diseases: A Meta-Analysis of Individual Patient Data. , 2019, , .		0
138	Reply to: â€œAccurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forwardâ€• Journal of Hepatology, 2020, 73, 466-467.	3.7	0
139	Biomarkers of liver fibrosis may behave differently depending on associated co-morbidities: need to consider the context of use. Clinical Gastroenterology and Hepatology, 2022, , .	4.4	0